Logo Image
|Articles|March 3, 2015

Canon Announces New Biomedical Company

Canon announced that it established Canon BioMedical, a wholly owned biomedical business to develop, manufacture, and market operations related to Canon’s life-science and molecular diagnostics platform.

 

Canon U.S.A announced on March 2, 2015 that it established Canon BioMedical to develop, manufacture, and market operations related to Canon’s life-science and molecular diagnostics platform. The company also plans to expand the use of Canon technology into other medical fields. Long-term growth includes untapped markets for Canon such as life science, healthcare, and medical analysis through the use of existing and future Canon technologies, as well as partnerships.

"We are truly excited and proud to launch Canon BioMedical, Inc., an American-born worldwide headquarters committed to bringing to market innovative technologies and solutions," said Joe Adachi, chairman and CEO, Canon U.S.A., Inc., in a press release. "We look forward to bringing Canon technology to clinicians and scientists all over the world in an effort to assist in improving human health and in advancing science."

Source: Canon

Related to this article

View more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more